Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease

Inclusion Criteria: * CD of the ileum, with or without involvement of the caecum or the right colon * Colonoscopy showing active lesions defined by a CDEISm score \>6 * Informed consent to participate in this study * Prescription of steroid treatments : Budesonide, Prednisone (or Prednisolone) independently from entry in study * Patients who respond to budesonide (initial dose 9 mg/d) or prednisone or prednisolone (initial dose 40 mg/d), defined as a 70 points decrease in CDAI between the pre-inclusion and the inclusion visit, * Patients colonized with AIEC on initial ileal biopsies. Exclusion Criteria: * Ileal stenosis that cannot be crossed by the endoscope, * Infliximab treatment received less than 8 weeks before inclusion in this study, * Adalimumab treatment received less than 4 weeks before inclusion in this study, * Vedolizumab treatment received less than 8 weeks before inclusion in the study, * Hypersensitivity to Ciprofloxacin, to other quinolones, or to any of the excipients (cellulose microcrystalline, crospovidone, maize starch, magnesium stearate, silica colloidal anhydrous,, hypromellose titanium dioxide E171, macrogol 4000,), * Tizanidine, Probenecid, Theophylline, Xanthine derivatives, Phenytoin, oral anticoagulants, and Ropinirole treatment, * Hypersensitivity to Rifaximin, or to any excipients (sodium starch glycolate type A, glycerol distearate, colloidal anhydrous silica, talc, microcrystalline cellulose, hypromellose, titanium dioxide, disodium edenta…